SCHEMBL114060

SCHEMBL114060

CCOC(OCC)c1cc(N)nc(SCc2ccccc2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.62
NPC1 O15118 4/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
HSP90AA1 P07900 1/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
TP53 P04637 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
ALDH1A1 P00352 2/20 0.42
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ADORA3 P0DMS8 4/20 0.42
ALOX15 P16050 1/20 0.42
SCN9A Q15858 1/20 0.41
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL114057 0.85 RAB9A (0.44) RAB9ANPC1SMN1; SMN2HSP90AA1KMT2A
SCHEMBL5634282 0.85 RAB9A (0.44) RAB9ANPC1SMN1; SMN2HSP90AA1KMT2A
SCHEMBL10882423 0.79 RAB9A (1.00) RAB9ANPC1SMN1; SMN2HSP90AA1KMT2A
SCHEMBL5634559 0.76 ADORA3 (0.38) RAB9ANPC1SMN1; SMN2HSP90AA1KMT2A
SCHEMBL1520825 0.75 RAB9A (0.78) RAB9ANPC1SMN1; SMN2HSP90AA1KMT2A
SCHEMBL6640353 0.73 DAO (0.41) RAB9ANPC1SMN1; SMN2KMT2ATP53
SCHEMBL112782 0.72 HPGD (0.59) RAB9ASMN1; SMN2KMT2AMEN1L3MBTL1
SCHEMBL8138707 0.72 RAB9A (0.73) RAB9ANPC1SMN1; SMN2HSP90AA1KMT2A
SCHEMBL6637055 0.72 RAB9A (0.68) RAB9ANPC1SMN1; SMN2HSP90AA1KMT2A
SCHEMBL1520770 0.72 RAB9A (0.78) RAB9ANPC1SMN1; SMN2HSP90AA1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK RAB9A 3413/4885NPC1 2786/4885SMN1; SMN2 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.